CYRX news & sentiment — Cryoport, Inc.

MAY 17·AD HOC NEWSMed

Cryoport Inc stock (US2289031005): Q1 revenue beats estimates in volatile cell and gene logistics market

Cryoport Inc (CYRX) reported Q1 2026 revenue that exceeded analyst estimates, despite continued net losses, navigating a volatile market for cell and gene therapy logistics. The company specializes in temperature-controlled logistics and biostorage, positioning itself as an infrastructure partner for the advanced therapies sector. Its performance reflects strong demand in core service lines amidst growth investments and cost pressures.

APR 7·富途牛牛

For Cryoport Insiders, Selling US$1.6m Of Shares Was A Smart Move

Insiders at Cryoport (NASDAQ: CYRX) sold US$1.6 million worth of shares over the last year, with Chairman Jerrell Shelton making the largest individual sale. This occurred despite recent stock gains, and the selling price was even below the current market value, suggesting insiders may have viewed a lower price as reasonable. While insiders still collectively own a notable 3.6% of the company, the consistent selling without any purchases raises concerns about their confidence in the stock's future performance.

MAR 17·MarketBeat

CryoPort (NASDAQ:CYRX) CFO Robert Stefanovich Sells 2,743 Shares

CryoPort's CFO, Robert Stefanovich, recently sold 2,743 shares of the company's stock for $8.00 per share, totaling $21,944, reducing his holdings by 0.97%. This follows a previous sale of 38,700 shares on March 12th. Despite mixed analyst ratings, the consensus is a "Moderate Buy" with a target price of $12.94.

$CYRX

Cryoport Inc stock (US2289031005): Q1 revenue beats estimates in volatile cell and gene logistics market

For Cryoport Insiders, Selling US$1.6m Of Shares Was A Smart Move

CryoPort (NASDAQ:CYRX) CFO Robert Stefanovich Sells 2,743 Shares

News on $CYRX